Lung Cancer | Specialty

The Multidisciplinary Care of Stage III NSCLC

May 2nd 2019

Dr. Kelly on the Benefit of Immunotherapy in Stage III NSCLC

May 2nd 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott & White Health's North Texas Cancer Centers and director of oncology at the Baylor Charles A. Sammons Cancer Center on the campus of Baylor University Medical Center, discusses the benefit of immunotherapy in patients with stage III non–small cell lung cancer (NSCLC).

Dr. Mason on the Role of Surgery in Stage III NSCLC

May 1st 2019

David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Healthcare System, chief of lung transplantation, Baylor University Medical Center, discusses the role of surgery in stage III non–small cell lung cancer.

Dr. Konduri Discusses Promise of NGS Testing in NSCLC

May 1st 2019

Kartik Konduri, MD, medical director, Chest Cancer Research and Treatment Center, Baylor Charles A. Sammons Cancer Center, Baylor Scott & White Health, discusses the promise of next-generation sequencing testing in patients with non–small cell lung cancer.

Dr. Nadler Discusses Role of PD-L1 in Squamous NSCLC

April 29th 2019

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the role of PD-L1 in patients with squamous non–small cell lung cancer.

Ongoing Research Builds Upon Advances in Stage III NSCLC, ALK+ Disease

April 27th 2019

Ronan J. Kelly, MD, MBA, addresses the paradigm shift in stage III unresectable non–small cell lung cancer before delving into the complex field of ALK-rearranged disease.

Dr. Chung on a Joint Analysis of Immunotherapy Trials in SCLC

April 27th 2019

Hyun C. Chung, MD, PhD, professor at Yonsei Cancer Center, Yonsei University College of Medicine in Seoul, Republic of Korea, discusses a joint analysis of the KEYNOTE-028 and KEYNOTE-158 trials in patients with advanced small cell lung cancer (SCLC).

Dr. Reimuth Discusses Studies Looking at Resistance to EGFR TKIs in NSCLC

April 25th 2019

Niels Reinmuth, MD, PhD, leader of the Thoracic Oncology Department, Asklepios Lung Clinic, discusses ongoing studies looking at resistance to EGFR TKIs in patients with EGFR-positive non–small cell lung cancer.

Dr. Mok Discusses Updated Data With Pembrolizumab in NSCLC

April 25th 2019

Tony Mok, MD, professor, Department of Clinical Oncology, Chinese University of Hong Kong, discusses updated data with pembrolizumab in patients with non–small cell lung cancer.

Dr. Garassino Discusses PROs With Durvalumab by PD-L1 Expression in Stage III NSCLC

April 25th 2019

Marina Chiara Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy, discusses patient reported outcomes with durvalumab by PD-L1 expression in patients with stage III unresectable non–small cell lung cancer.

Chemoimmunotherapy Emerges as Frontline Standard in Squamous NSCLC

April 25th 2019

Eric S. Nadler, MD, discusses key data with immunotherapy in the treatment of patients with metastatic squamous non–small cell lung cancer.

Focus in Oncogene-Driven NSCLC Turns to Sequencing Strategies, Overcoming Resistance

April 25th 2019

Kartik Konduri, MD, discusses the use of combination therapies and newer agents in patients with targetable driver mutations.

Dr. Drilon on Activity of Larotrectinib in TRK Fusion-Positive NSCLC

April 25th 2019

Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the activity of larotrectinib (Vitrakvi) in patients with TRK fusion–positive non–small cell lung cancer.

Multimodality Treatment Approach Necessary in Stage III NSCLC

April 24th 2019

David P. Mason, MD, discusses the available treatment approaches for patients with locally advanced non–small cell lung cancer.

Dr. Mansfield on the Current Treatment Paradigm in SCLC

April 24th 2019

Aaron S. Mansfield, MD, associate professor of oncology, consultant in the Division of Medical Oncology, Mayo Clinic, discusses the current treatment paradigm for patients with extensive-stage small cell lung cancer (SCLC) and highlights ongoing research in the field.

Dr. Ramalingam on the Use of Osimertinib in Clinical Trial and Real-World Settings

April 24th 2019

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the impact of osimertinib (Tagrisso) in both clinical trial and real-world settings.

Dr. Konduri on Treatment Options for Patients With EGFR-Mutant NSCLC

April 24th 2019

Kartik Konduri, MD, medical director, Chest Cancer Research and Treatment Center, Baylor Charles A. Sammons Cancer Center, Baylor Scott & White Health, discusses treatment options available for patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Mason on Standard Treatment Approaches in Stage III NSCLC

April 23rd 2019

David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Healthcare System, chief of lung transplantation, Baylor University Medical Center, discusses standard treatment approaches available for patients with stage III non–small cell lung cancer (NSCLC).

Dr. Konduri on Sequencing Therapy in EGFR+ NSCLC

April 18th 2019

Kartik Konduri, MD, co-medical director of the Lung Cancer Center of Excellence, Baylor Charles A. Sammons Cancer Center, on the campus of Baylor University Medical Center, discusses sequencing therapy in patients with EGFR-positive non–small cell lung cancer.

Dr. Mansfield Discusses Challenges in SCLC

April 18th 2019

Aaron S. Mansfield, MD, associate professor of oncology, consultant in the Division of Medical Oncology, Mayo Clinic, discusses challenges in the treatment of patients with small cell lung cancer.